Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
    83.
    发明授权
    Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof 失效
    丙泊酚的氨基酸衍生前药,组合物,用途及其结晶形式

    公开(公告)号:US08067455B2

    公开(公告)日:2011-11-29

    申请号:US12572505

    申请日:2009-10-02

    IPC分类号: A61K31/415

    CPC分类号: C07C229/22

    摘要: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.

    摘要翻译: 本发明提供异丙酚及其结晶形式的前药,制备异丙酚前药及其结晶形式的方法,异丙酚前药及其结晶形式的药物组合物,使用异丙酚前药及其结晶形式的方法及其药物组合物 治疗诸如头痛,化疗后或术后手术恶心和呕吐,神经变性障碍和情绪障碍的疾病或障碍。

    2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
    85.
    发明授权
    2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof 失效
    2'-C-甲基 - 呋喃核糖基胞苷前药,药物组合物及其用途

    公开(公告)号:US08058260B2

    公开(公告)日:2011-11-15

    申请号:US11752214

    申请日:2007-05-22

    申请人: Mark A. Gallop

    发明人: Mark A. Gallop

    IPC分类号: A61K31/70 C07H19/067

    CPC分类号: C07H19/06

    摘要: The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl cytidine prodrugs and pharmaceutical compositions thereof to treat viral diseases such as hepatitis C.

    摘要翻译: 本公开内容提供2'-C-甲基 - 呋喃核糖胞苷前体药物,制备2'-C-甲基 - 呋喃核糖胞苷前体药物的方法,2'-C-甲基 - 呋喃核糖胞苷前体药物组合物,以及使用2'- C-甲基 - 呋喃核糖基胞苷前体药物及其药物组合物,用于治疗病毒性疾病如丙型肝炎。

    Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
    88.
    发明授权
    Acyloxyalkyl carbamate prodrugs, methods of synthesis and use 失效
    氨基甲酸氨基甲酸烷基酯前药,合成和使用方法

    公开(公告)号:US07749985B2

    公开(公告)日:2010-07-06

    申请号:US12506961

    申请日:2009-07-21

    IPC分类号: A61K31/66 C07F9/02

    CPC分类号: C07F9/301

    摘要: Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders such as mild cognitive impairment, cognitive impairment associated with Alzheimer's disease Alzheimer's disease, depression, anxiety, and epilepsy are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, which are suitable for oral administration and sustained release oral dosage forms are also disclosed.

    摘要翻译: 3-氨基丙基次膦酸的氨基甲酸烷基酯氨基甲酸酯前药及其类似物,3-氨基丙基次膦酸及其类似物的制备酰氨基烷基氨基甲酸酯前药的方法及其类似物,使用3-氨基丙基次膦酸及其类似物的酰氨基烷基氨基甲酸酯前药的方法和包含酰氨基烷基氨基甲酸酯前药3 - 氨基丙基次膦酸及其类似物用于治疗疾病或病症如轻度认知障碍,与阿尔茨海默氏病相关的认知障碍阿尔茨海默氏病,抑郁症,焦虑和癫痫。 还公开了适用于口服给药和缓释口服剂型的3-氨基丙基次膦酸的氨基氧基烷基氨基甲酸酯前药及其类似物。

    Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
    89.
    发明授权
    Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs 失效
    用于增强口服吸收和药物全身生物利用度的胆汁酸衍生化合物

    公开(公告)号:US07678782B2

    公开(公告)日:2010-03-16

    申请号:US11483770

    申请日:2006-07-11

    IPC分类号: A61K31/56 C07J9/00

    摘要: Disclosed are methods for providing enhanced systemic blood concentrations of orally delivered drugs that are incompletely translocated across the intestinal wall of an animal. Also disclosed are methods for the sustained release of drugs, whether poorly or readily bioavailable via oral delivery to animals. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.

    摘要翻译: 公开了用于提供不完全易位穿过动物肠壁的口服递送药物的增强的全身血液浓度的方法。 还公开了用于药物持续释放的方法,无论是通过口服递送给动物还是很少或容易生物利用。 此外,还公开了用于这些方法的化合物和药物组合物。